Novocure’s response to COVID-19

Novocure’s response to COVID-19

Important information for our patients, caregivers and providers

Learn More
STELLAR Trial Results Published in The Lancet Oncology

STELLAR Trial Results Published in The Lancet Oncology

focusing on<br><span>the details</span>

focusing on
the details

Dario Garcia-Carracedo sees how his work as Associate Director of Medical Affairs fits into the big picture at Novocure.

unafraid <br><span>to innovate</span>

to innovate

Katia Felix, Associate Director of Global Strategic Development, moved into a new role created for her after sharing an idea that could positively impact the company.

Medicare<br><span> update</span>


The Medicare Durable Medical Equipment Medicare Administrative Contractors have released a final local coverage determination providing coverage of Novocure’s cancer treatment for Medicare beneficiaries with newly diagnosed glioblastoma.

Learn More
FDA approves Novocure’s cancer treatment for MPM

FDA approves Novocure’s cancer treatment for MPM

The U.S. FDA has approved Tumor Treating Fields for the treatment of unresectable malignant pleural mesothelioma.


the story
of Novocure

In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with nearly 600 employees and operations in the U.S., Europe and Asia.

Learn More

we can leverage physics to fight cancer

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and potentially causing cancer cells to die.


explore our clinical pipeline

Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.


we are dedicated to improving the lives of cancer patients

Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.